Generic anti-malarial may treat COVID-19 - Raymond James [Seeking Alpha]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Seeking Alpha
Healthcare Generic anti-malarial may treat COVID-19 - Raymond James Mar. 10, 2020 6:23 PM ET | AbbVie Inc. (ABBV) Jason Aycock A generic drug used to treat malaria may be as promising as any that companies are currently scrambling for to treat COVID-19, the coronavirus-related disease spreading rapidly, Raymond James says. Analyst Steven Seedhouse says chloroquine - a longtime oral anti-malarial that costs pennies per dose - could turn out "more effective, scalable, and affordable" than the candidates being studied by companies including AbbVie (NYSE: GILD REGN MRNA GSK PFE After very early indications of efficacy in China, chloroquine is seeing increased demand suggesting it may be seeing real-world use already, though ultimate efficacy depends on data that still need to be gathered. Click to subscribe to real-time analytics on ABBV Now read: Zentalis Pharmaceuticals Seeks Development Funding From IPO »
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie Inc. (NYSE: ABBV) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $206.00 price target on the stock.MarketBeat
- Antibody Drug Conjugates Contract Manufacturing Market Analysis and Forecast (2025-2030) by Linker, Condition, End Use and Region - Industry Set to Experience 11.8% CAGR Over the Forecast Period [Yahoo! Finance]Yahoo! Finance
- AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy [Yahoo! Finance]Yahoo! Finance
- Specialty Pharmaceuticals Research Report: Increased Reimbursement Through Medical and Pharmacy Benefits Driving the Market, Reaching $965 Billion by 2030 [Yahoo! Finance]Yahoo! Finance
- Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 10/30/24 - Beat
ABBV
Sec Filings
- 11/4/24 - Form S-8
- 11/4/24 - Form S-8
- 11/4/24 - Form 10-Q
- ABBV's page on the SEC website